Quick Answer
Lantern Pharma Inc. reported Cash and Equivalents of $4.42 million for fiscal year 2025.
Lantern Pharma Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.42M | -41.1% |
| 2024 | $7.51M | -65.8% |
| 2023 | $21.94M | -41.0% |
| 2022 | $37.20M | -27.8% |
| 2021 | $51.52M | +167.9% |
| 2020 | $19.23M | +1460.8% |
| 2019 | $1.23M | +176.8% |
| 2018 | $445.2K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.39M | +3.5% | +38.4% |
| June 30, 2025 | $6.06M | -53.3% | -5.0% |
| March 31, 2025 | $6.38M | -65.3% | -15.1% |
| December 31, 2024 | $7.51M | -65.8% | -7.3% |
| September 30, 2024 | $8.10M | -68.3% | -37.6% |
| June 30, 2024 | $12.98M | -54.3% | -29.3% |
| March 31, 2024 | $18.36M | -43.5% | -16.3% |
| December 31, 2023 | $21.94M | -41.0% | -14.2% |
- Lantern Pharma Inc. showed a decrease of -41.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Lantern Pharma Inc.’s cash and equivalents has grown by 893.5% (from $445.2 thousand to $4.42 million).
- The most recent figure is from Lantern Pharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: